Magnetically Activated Piezoelectric 3D Platform Based on Poly(Vinylidene) Fluoride Microspheres for Osteogenic Differentiation of Mesenchymal Stem Cells

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Guillot-Ferriols, Maria
  • Inmaculada Garcia-Briega, Maria
  • Costa, Carlos M.
  • Lanceros-Mendez, Senentxu

Grupos

Abstract

Mesenchymal stem cells (MSCs) osteogenic commitment before injection enhances bone regeneration therapy results. Piezoelectric stimulation may be an effective cue to promote MSCs pre-differentiation, and poly(vinylidene) fluoride (PVDF) cell culture supports, when combined with CoFe2O4 (CFO), offer a wireless in vitro stimulation strategy. Under an external magnetic field, CFO shift and magnetostriction deform the polymer matrix varying the polymer surface charge due to the piezoelectric effect. To test the effect of piezoelectric stimulation on MSCs, our approach is based on a gelatin hydrogel with embedded MSCs and PVDF-CFO electroactive microspheres. Microspheres were produced by electrospray technique, favouring CFO incorporation, crystallisation in beta-phase (85%) and a crystallinity degree of around 55%. The absence of cytotoxicity of the 3D construct was confirmed 24 h after cell encapsulation. Cells were viable, evenly distributed in the hydrogel matrix and surrounded by microspheres, allowing local stimulation. Hydrogels were stimulated using a magnetic bioreactor, and no significant changes were observed in MSCs proliferation in the short or long term. Nevertheless, piezoelectric stimulation upregulated RUNX2 expression after 7 days, indicating the activation of the osteogenic differentiation pathway. These results open the door for optimising a stimulation protocol allowing the application of the magnetically activated 3D electroactive cell culture support for MSCs pre-differentiation before transplantation.

Datos de la publicación

ISSN/ISSNe:
2310-2861, 2310-2861

GELS  MDPI

Tipo:
Article
Páginas:
-
Factor de Impacto:
0,693 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 5

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • mesenchymal stem cells; osteoblastogenesis; piezoelectricity; poly(vinylidene) fluoride; hydrogel

Proyectos asociados

RED DE INNOVACION EN TECNOLOGIAS MEDICAS Y SANITARIAS - RED ITEMAS

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

RD09/0077/00156 . INSTITUTO DE SALUD CARLOS III . 2010

MECANISMOS TRANSCRIPCIONALES IMPLICADOS EN EL HIGADO GRASO NO ALCOHOLICO DE ORIGEN METABOLICO E IATROGENICO: INFLUENCIA DE LA RESISTENCIA A LA INSULINA

Investigador Principal: RAMIRO JOVER ATIENZA

PI10/00194 . INSTITUTO DE SALUD CARLOS III . 2010

METABONOMICA Y CITOMICA COMO NUEVOS PARADIGMAS Y ESTRATEGIAS EXPERIMENTALES PARA EL ESTUDIO DE LOS MECANISMOS DE HEPATOTOXICIDAD DE FARMACOS, PREDICCION DE SU POTENCIAL HEPATOTOXICO Y LA TRANSICION DE HEPATITIS I ATROGENICA A AUTOINMUNE.

Investigador Principal: MARÍA TERESA DONATO MARTÍN

PI10/00923 . INSTITUTO DE SALUD CARLOS III . 2010

APROXIMACIONES METABONÓMICAS PARA EL ESTUDIO DE LA HEPATOTOXICIDAD IDIOSINCRÁSICA CON BASE METABÓLICA Y LA IDENTIFICACIÓN DEL AGENTE CAUSAL.

Investigador Principal: MARÍA TERESA DONATO MARTÍN

PI13/00986 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

MÉDULA ÓSEA ARTIFICIAL PARA PERSONALIZAR EL TRATAMIENTO DE PACIENTES DE CÁNCERES DE SANGRE-TISSUE MIELOMA.

Investigador Principal: JOSE LUIS GOMEZ RIBELLES

2015_0800_CPC_GOMEZ . CONSELLERIA DE EDUCACION . 2016

EUTOXRISK21. AN INTEGRATED EUROPEAN ‘FLAGSHIP’ PROGRAM DRIVING MECHANISM-BASED.

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

681002_EUTOXRISK_CASTELL_H2020-PHC-33-2015 . COMISION EUROPEA . 2016

Tu hospital investiga RRI.

Investigador Principal: ANA ISABEL JUAN ROCH

FCT-18-14018 . FUNDACION ESPAÑOLA PARA LA CIENCIA Y LA TECNOLOGIA . 2019

IMPROVING FEASIBILITY OF LIVER CELL THERAPY: NEW CELL SOURCES AND STRATEGIES TO IMPROVE THE CLINICAL OUTCOME. (PROYECTO)

Investigador Principal: LAIA TOLOSA PARDO

CP16/00097 . INSTITUTO DE SALUD CARLOS III . 2017

ESTANCIA DE PERSONAL INVESTIGADOR DOCTOR EN CENTROS DE INVESTIGACION RADICADOS FUERA DE LA COMUNIDAD VALENCIANA. Laia Tolosa Pardo

Investigador Principal: LAIA TOLOSA PARDO

BEST2020/144 . CONSELLERIA DE EDUCACION . 2020

Nuevas tecnologías traslacionales para el tratamiento de enfermedades hepáticas: preacondicionamiento del hígado, nuevas fuentes celulares y biomateriales en terapia celular.

Investigador Principal: LAIA TOLOSA PARDO

PI21/00223 . INSTITUTO DE SALUD CARLOS III . 2022

Characterisation of human variability in Toxicodynamics: towards the development of quantitative Adverse Outcome Pathways (qAOPs).

Investigador Principal: LAIA TOLOSA PARDO

OC/EFSA/SCER/2021/03 . EUROPEAN FOOD SAFETY AUTHORITY . 2021

Cita

Compartir